Should I buy or sell Landos Biopharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Landos Biopharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LABP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LABP, but not buy additional shares or sell existing shares. View LABP analyst ratings or view top-rated stocks .

What is Landos Biopharma's stock price target for 2024?

1 equities research analysts have issued twelve-month price objectives for Landos Biopharma's stock. Their LABP share price targets range from $20.42 to $20.42. On average, they predict the company's share price to reach $20.42 in the next year. This suggests that the stock has a possible downside of 5.5%. View analysts price targets for LABP or view top-rated stocks among Wall Street analysts .

How have LABP shares performed in 2024?

Landos Biopharma's stock was trading at $3.66 on January 1st, 2024. Since then, LABP shares have increased by 490.4% and is now trading at $21.61. View the best growth stocks for 2024 here .

Are investors shorting Landos Biopharma?

Landos Biopharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,900 shares, an increase of 345.5% from the March 15th total of 1,100 shares. Based on an average trading volume of 23,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the shares of the stock are sold short. View Landos Biopharma's Short Interest .

When is Landos Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our LABP earnings forecast .

How were Landos Biopharma's earnings last quarter?

Landos Biopharma, Inc. (NASDAQ:LABP) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by $0.08.

When did Landos Biopharma's stock split?

Landos Biopharma shares reverse split on Friday, May 26th 2023. The 1-10 reverse split was announced on Friday, May 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Landos Biopharma IPO?

Landos Biopharma (LABP) raised $101 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Raymond James was co-manager.

Who are Landos Biopharma's major shareholders?

Landos Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (1.60%). Insiders that own company stock include Josep Bassaganya-Riera and Rtw Investments, Lp. View institutional ownership trends .

How do I buy shares of Landos Biopharma?

Shares of LABP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LABP

Landos Biopharma (LABP) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free LABP Stock Alerts

$21.66

-0.01 (-0.05%)

(As of 10:31 AM ET)

Compare

Today's Range: $21.55
▼
$21.66
50-Day Range: $5.18
▼
$21.67
52-Week Range: $2.50
▼
$21.87

Volume: 8,696 shs
Average Volume: 22,370 shs
Market Capitalization: $67.51 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.42

Get Landos Biopharma alerts:

Landos Biopharma MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 5.5% Downside
$20.42 Price Target
Short Interest: Healthy
0.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.37
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.19) to ($1.68) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.34 out of 5 stars

Medical Sector

875th out of 914 stocks

Pharmaceutical Preparations Industry

406th out of 424 stocks

1.0

Analyst's Opinion

Consensus Rating
Landos Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Landos Biopharma has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.17% of the float of Landos Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Landos Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Landos Biopharma has recently increased by 345.45%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Landos Biopharma does not currently pay a dividend.
Dividend Growth
Landos Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LABP.

3.0

News and Social Media Coverage

News Sentiment
Landos Biopharma has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Landos Biopharma this week, compared to 1 article on an average week.
Search Interest
3 people have searched for LABP on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Landos Biopharma to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Landos Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.30% of the stock of Landos Biopharma is held by insiders.
Percentage Held by Institutions
49.06% of the stock of Landos Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Landos Biopharma are expected to grow in the coming year, from ($2.19) to ($1.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Landos Biopharma is -6.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Landos Biopharma is -6.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Landos Biopharma has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

About Landos Biopharma Stock (NASDAQ:LABP)

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

LABP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LABP Stock News Headlines

April 17, 2024 | msn.com

Landos Biopharma (LABP) Price Target Increased by 154.20% to 12.96

April 16, 2024 | prnewswire.com

Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

March 27, 2024 | businesswire.com

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP

March 27, 2024 | finanznachrichten.de

Landos Biopharma, Inc.: AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

March 27, 2024 | markets.businessinsider.com

Leerink Partners Remains a Hold on Landos Biopharma (LABP)

March 26, 2024 | prnewswire.com

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABP

March 26, 2024 | markets.businessinsider.com

AbbVie To Acquire Landos Biopharma At $20.42/share In Cash

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

March 26, 2024 | bizjournals.com

AbbVie to buy Landos Biopharma for $137 million

March 26, 2024 | finance.yahoo.com

Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?

March 25, 2024 | investorplace.com

Why Is Landos Biopharma (LABP) Stock Up 168% Today?

March 25, 2024 | prnewswire.com

Shareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVie

March 25, 2024 | businesswire.com

LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders

March 25, 2024 | reuters.com

AbbVie to buy Landos to expand pipeline of immunity-related illnesses

March 25, 2024 | prnewswire.com

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

March 25, 2024 | globenewswire.com

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

March 21, 2024 | investorplace.com

LABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023

March 21, 2024 | finanznachrichten.de

Landos Biopharma, Inc.: Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

March 21, 2024 | benzinga.com

Recap: Landos Biopharma Q4 Earnings

March 21, 2024 | globenewswire.com

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

March 6, 2024 | benzinga.com

Xontogeny, LLC's Net Worth

March 5, 2024 | finance.yahoo.com

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

January 10, 2024 | benzinga.com

Ambrx Biopharma Stock (NASDAQ:AMAM) Dividends: History, Yield and Dates

January 8, 2024 | finance.yahoo.com

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation

November 22, 2023 | msn.com

Landos’s NX-13 shows symptom relief in Phase Ib ulcerative colitis trial

November 21, 2023 | finanznachrichten.de

Landos Biopharma, Inc.: Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and Colitis

See More Headlines

Receive LABP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Landos Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LABP
CUSIP: N/A
CIK: 1785345
Web: landosbiopharma.com
Phone: 540-218-2232
Fax: N/A
Employees: 19
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.42
High Stock Price Target: $20.42
Low Stock Price Target: $20.42
Potential Upside/Downside: -5.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,930,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -54.92%
Return on Assets: -49.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.09
Quick Ratio: 6.09

Sales & Book Value

Annual Sales: $18 million
Price / Sales: 3.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.20 per share
Price / Book: 2.12

Miscellaneous

Outstanding Shares: 3,117,000
Free Float: 3,076,000
Market Cap: $67.36 million
Optionable: Not Optionable
Beta: 0.14

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Gregory Oakes (Age 56)
President, CEO & Director
Comp: $1.04M
Mr. Timothy M. Mayleben M.B.A. (Age 63)
Principal Financial Officer & Director
Comp: $555.99k
Dr. Fabio Cataldi M.D. (Age 57)
Executive VP & Chief Medical Officer
Comp: $516.68k
Ms. Rebecca Mosig Ph.D.
Vice President of Corporate Development
Dr. Josep Bassaganya-Riera DVM (Age 49)
Ph.D., Advisor
Comp: $1.79M

Key Competitors

View All Competitors

Institutional Ownership

Deltec Asset Management LLC
Bought 50,000 shares on 4/17/2024
Ownership: 1.603%

View All Institutional Transactions

LABP Stock Analysis - Frequently Asked Questions

Should I buy or sell Landos Biopharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Landos Biopharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LABP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LABP, but not buy additional shares or sell existing shares.
View LABP analyst ratings or view top-rated stocks.
What is Landos Biopharma's stock price target for 2024?: 1 equities research analysts have issued twelve-month price objectives for Landos Biopharma's stock. Their LABP share price targets range from $20.42 to $20.42. On average, they predict the company's share price to reach $20.42 in the next year. This suggests that the stock has a possible downside of 5.5%.
View analysts price targets for LABP or view top-rated stocks among Wall Street analysts.
How have LABP shares performed in 2024?: Landos Biopharma's stock was trading at $3.66 on January 1st, 2024. Since then, LABP shares have increased by 490.4% and is now trading at $21.61.
View the best growth stocks for 2024 here.
Are investors shorting Landos Biopharma?: Landos Biopharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,900 shares, an increase of 345.5% from the March 15th total of 1,100 shares. Based on an average trading volume of 23,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the shares of the stock are sold short.
View Landos Biopharma's Short Interest.
When is Landos Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our LABP earnings forecast.
How were Landos Biopharma's earnings last quarter?: Landos Biopharma, Inc. (NASDAQ:LABP) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by $0.08.

When did Landos Biopharma's stock split?: Landos Biopharma shares reverse split on Friday, May 26th 2023. The 1-10 reverse split was announced on Friday, May 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
When did Landos Biopharma IPO?: Landos Biopharma (LABP) raised $101 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Raymond James was co-manager.
Who are Landos Biopharma's major shareholders?: Landos Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (1.60%). Insiders that own company stock include Josep Bassaganya-Riera and Rtw Investments, Lp.
View institutional ownership trends.
How do I buy shares of Landos Biopharma?: Shares of LABP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LABP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial